Back
MSH2, EPCAMHGNC PubMedPenetrance update

Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort

Schuler A, Engel C, Ahadova A, et al. — JCO Precis Oncol 2026 · November 2026
Relevance score
7/10
Disease / domain
Lynch syndrome — urothelial carcinoma
Source
PubMed
PMID 43024847

Gene / mechanism

MSH2, EPCAM

Germline pathogenic variants in MMR genes; urothelial risk associated with MSH2/EPCAM carrier status

Summary

Urothelial carcinoma contributes substantially to Lynch syndrome-associated morbidity and mortality. The authors retrospectively analysed 3,274 genetically confirmed adult carriers from the nationwide German Consortium for Familial Intestinal Cancer registry, with clinical and pathological validation of diagnoses, centralised review, MMR immunohistochemistry and MSI testing of available tumours. In total, 144 carriers (4.4%) had 224 primary urothelial carcinomas, at a median age of 55 years at first diagnosis; it was the first malignancy in 34.7% of them and arose in the upper urinary tract in 56.4% of tumours with known location. In multivariable analysis, MSH2/EPCAM carrier status was associated with urothelial carcinoma risk (HR 4.43; 95% CI 2.85-6.89), whereas previous colorectal cancer and family history of urothelial carcinoma were not. Of 31 lesions analysed, 93.6% were dMMR and 96.8% MSI-high, and only 10.1% of patients with diagnostic information were diagnosed during urological or oncological surveillance.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

The most striking figure is that urothelial carcinoma is the first cancer in one third of affected patients, which argues for specific counselling of MSH2 carriers about urinary symptoms. Retrospective case finding based on ICD-10 codes risks under-ascertainment, despite manual validation. The authors call for prospective evaluation of genotype-adapted surveillance: the right caution before writing any screening modality into guidelines.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 2/3Evidence 3/3Novelty 1/2Sample 1/1Publication 0/1

Clinical impact: 2/3 · Evidence strength: 3/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 7/10

Keywords

Lynch syndromeMSH2urothelial carcinomamicrosatellite instabilitysurveillance
Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime